When my husband, Donnie, first became sick with pulmonary fibrosis (PF), we were unsure of the road that lay before us. His diagnosis finally came after specialized blood work and video-assisted ...

Two pivotal Phase 3 trials of Haduvio are expected to launch this year and, if positive, may support applications seeking its ...

With chronic kidney disease a risk for transplant recipients, columnist Sam Kirton writes about the need for more living kidney donors.

Dosing is now underway in an IPF clinical trial testing the inhaled therapy LTI-03, following the lifting of an FDA hold late last year.

The alarm goes off at 4:30 a.m. It is not a welcome awakening, but a stark reminder of the day ahead. The purpose of the alarm isn’t to ensure that my wife, Susan, and I are up to catch a flight that ...

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...

[vc_row][vc_column][vc_column_text] Tipelukast (MN-001) is an oral macromolecular formulation developed originally by Kyorin Pharmaceuticals and now in clinical trials in the United States by ...

Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

AbbVie’s portfolio of antibodies for the potential treatment of idiopathic pulmonary fibrosis (IPF) now includes DJS-002 — a first-in-class antibody directed against lysophosphatidic acid receptor-1 ...

The U.S. Food and Drug Administration (FDA) has approved Jascayd (nerandomilast), taken as oral tablets, as a treatment for adults with progressive pulmonary fibrosis (PPF), in which lung scarring ...